Sanjay Aggarwal, MD
Pulmonary Disease · Lake Jackson, TXNPI 1801878608
Payments from drug & device makers
Across 492 payments — averaging $58.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$18K
- AstraZeneca$2K
- Viiv Healthcare Company$2K
- Inspire Medical Systems, Inc.$1K
- Mylan Specialty L.p.$725
- Boehringer Ingelheim$494
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$18,10063%
- Travel & lodging$9703%
- Food & beverage$9,55433%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 157 | $18,475 |
| AstraZeneca | 93 | $2,457 |
| Viiv Healthcare Company | 1 | $1,600 |
| Inspire Medical Systems, Inc. | 24 | $1,479 |
| Mylan Specialty L.p. | 34 | $725 |
| Boehringer Ingelheim | 27 | $494 |
| Harmony Biosciences LLC | 24 | $491 |
| Insmed, Inc. | 17 | $352 |
| Baxter Healthcare | 9 | $304 |
| Philips North America LLC | 14 | $265 |
| Regeneron Healthcare Solutions, Inc. | 11 | $247 |
| Amgen | 8 | $177 |
| Chiesi USA, Inc. | 2 | $148 |
| Sunovion Pharmaceuticals Inc. | 12 | $128 |
| Vifor Pharma, Inc. | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 4 | $99 |
| Idorsia Pharmaceuticals US Inc | 5 | $98 |
| Gilead | 5 | $89 |
| Electromed, Inc. | 3 | $83 |
| Johnson & Johnson | 4 | $82 |
| Merck | 4 | $79 |
| Jazz Pharmaceuticals Inc. | 4 | $71 |
| Eisai Inc. | 3 | $58 |
| Optinose US, Inc. | 3 | $56 |
| Mallinckrodt Hospital Products Inc. | 2 | $53 |
| Genentech USA, Inc. | 3 | $51 |
| Circassia Inc. | 3 | $49 |
| Pfizer | 2 | $43 |
| Novo Nordisk | 1 | $40 |
| Grifols USA, LLC | 2 | $39 |
| Bayer | 2 | $30 |
| Biogen | 1 | $28 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Resmed Corp | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $19 |
| Sanofi | 1 | $18 |
| Viatris Specialty LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,643 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 963 | $739,818 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 294 | $224,381 |
| OfevNintedanib Esylate | 16 | $203,903 |
| Breo ElliptaFluticasone/Vilanterol | 125 | $64,343 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 92 | $48,446 |
| XareltoRivaroxaban | 40 | $42,450 |
| EliquisApixaban | 36 | $34,763 |
| BelsomraSuvorexant | 48 | $21,045 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $18,584 |
| Varenicline Tartrate | 91 | $18,235 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 604 | $16,642 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $14,191 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 111 | $12,242 |
| Spiriva RespimatTiotropium Bromide | 23 | $12,119 |
| Wixela InhubFluticasone Propion/Salmeterol | 117 | $10,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $18,475 | $858,7201,201 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $494 | $242,06188 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,457 | $238,573343 claims |
| Johnson & JohnsonXarelto | $82 | $42,45040 claims |
| PfizerEliquis | $43 | $34,76336 claims |
| MerckBelsomra, Dulera | $79 | $24,92260 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Lake Jackson
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.